Início › Leucemia Mieloide Aguda › Pensilvânia

Ensaios clínicos de Leucemia Mieloide Aguda em Pensilvânia

45 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Pensilvânia.

Cidades em Pensilvânia

Texto oficial do estudo (Inglês)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Thomas Jefferson University Hospital, Philadelphia

RecrutandoFase 2

Idades 60 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07437950

Assessment of Geriatric Evaluations Impact on New AML Guidance

Abramson Cancer Center at University of Pennsylvania, Philadelphia

RecrutandoEstudo observacional

Idades 50 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05909501

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Geisinger Medical Center, Danville
e mais 7

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital of Philadelphia, Philadelphia

RecrutandoEstudo observacional

Idades de 0 a 38 · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
e mais 4

RecrutandoFase 2

Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
e mais 6

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh of UPMC, Pittsburgh

RecrutandoFase 1

Até 21 anos · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
e mais 4

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Geisinger Medical Center, Danville
Thomas Jefferson University Hospital, Philadelphia
UPMC Hillman Cancer Center, Pittsburgh
e mais 1

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
e mais 6

RecrutandoFase 2

Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Children's Hospital, Hershey
e mais 3

RecrutandoFase 3

6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

University of Pennsylvania, Philadelphia

RecrutandoFase 1/2

30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Spoknwrd Clinical Trials Inc., Easton

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06824168

A Study of BGB-11417 in Participants With Myeloid Malignancies

Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT04771130

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

UPENN Perelman Center for Advanced Medicine, Philadelphia

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06846606

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Geisinger Medical Center, Danville
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh of UPMC, Pittsburgh

RecrutandoFase 3

Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07022678

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Cancer Care Associates of York, York

RecrutandoEstudo observacional

Idades 0 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Pittsburgh PA-PITT, Pittsburgh

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

US-Pittsburgh PA-PITT, Pittsburgh

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT07223814

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Children's Hospital, Hershey
e mais 3

RecrutandoFase 1/2

Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Children's Hospital of Philadelphia, Philadelphia

RecrutandoFase 3

29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Pennsylvania, Philadelphia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

UMPC Hillman Cancer Center, Pittsburgh

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07565220

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

UPMC Hillman Cancer Center, Pittsburgh

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06529731

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

University of Pennsylvania, Philadelphia

RecrutandoFase 2/3

Idades de 18 a 80 · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06788756

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia

RecrutandoFase 1

Idades de 1 a 30 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06177067

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Penn Medicine Abramson Cancer Center, Philadelphia

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT05442216

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

University of Pennsylvania, Philadelphia

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 9 de jul. de 2026 · NCT05945849

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Children's Hospital of Philadelphia, Philadelphia

Recrutando

Até 25 anos · Todos os sexos · Atualizado em 8 de jul. de 2026 · NCT03810196

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia

RecrutandoFase 1

Idades de 0 a 29 · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT07464951

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Penn State Milton S. Hershey Cancer Center, Hershey
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh, Pittsburgh
e mais 3

RecrutandoEstudo observacional

Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Penn Medicine - Abramson Cancer Center Perelman, Philadelphia

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT04068597

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

University of Pennsylvania, Philadelphia

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 14 de mai. de 2026 · NCT06222580

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Pennsylvania State University Hershey Medical Center, Hershey

RecrutandoFase 1

Até 21 anos · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT05101551

Massage Impact on Sleep in Pediatric Oncology

Children's Hospital of Philadelphia, Philadelphia

Recrutando

Idades de 12 a 21 · Todos os sexos · Atualizado em 15 de abr. de 2026 · NCT06892158

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Allegheny Health Network, Pittsburgh

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

University of Pennsylvania, Philadelphia

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de mar. de 2026 · NCT04990102

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Thomas Jefferson University Hospital, Philadelphia

RecrutandoFase 1

Idades 12 e acima · Todos os sexos · Atualizado em 16 de mar. de 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Hospital of the University of Pennsylvania, Philadelphia

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT05735184

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.